Can I Take Vitamin B6 with CJC-1295?

What Is CJC-1295 and Why Are People Combining It with Supplements?

CJC-1295 modified GRF (sometimes called mod GRF 1-29) is a synthetic analogue of growth hormone-releasing hormone (GHRH). Compounding pharmacies prepare it under 503A status in the United States for physician-supervised use. The peptide binds pituitary GHRH receptors, triggering pulsatile release of endogenous growth hormone and, downstream, hepatic production of IGF-1.

How CJC-1295 Works at the Receptor Level

After subcutaneous injection, CJC-1295 occupies GHRH receptors on somatotroph cells in the anterior pituitary. Binding activates adenylyl cyclase, raises intracellular cAMP, and promotes GH secretion over a window of approximately 30 minutes. Modified GRF 1-29 lacks the drug affinity complex (DAC) found in the longer-acting CJC-1295 with DAC, so its half-life is roughly 30 minutes rather than several days. A 2006 pharmacokinetic study by Jetté et al. In the Journal of Clinical Endocrinology and Metabolism described GHRH analogue kinetics in healthy adults.

Why Patients Add Vitamin B6

Patients using peptide protocols often take a stack of co-supplements. B6 is common because it appears in virtually every multivitamin, is sold as a standalone "hormone support" product, and is sometimes recommended by coaches to support serotonin and dopamine synthesis. Some online protocols incorrectly suggest B6 "enhances" GH signaling. That claim has no peer-reviewed basis.

The 503A Compounding Context

CJC-1295 is not FDA-approved as a finished drug product. Compounding under 503A means a licensed physician must prescribe it for a specific patient, and quality can vary between compounding pharmacies. This regulatory context matters because it limits formal drug-interaction studies: no pharmaceutical manufacturer has conducted the kind of randomized, controlled pharmacokinetic work that would definitively characterize every supplement co-administration scenario.

Is There a Direct Pharmacokinetic Interaction Between B6 and CJC-1295?

No direct pharmacokinetic interaction has been identified. The two compounds do not share metabolic pathways in a way that would cause one to raise or lower blood levels of the other.

Metabolism of CJC-1295

CJC-1295 is a 29-amino-acid peptide. Like all therapeutic peptides, it is cleared primarily by dipeptidyl peptidase IV (DPP-IV) cleavage and general proteolytic degradation in plasma and tissues. It does not rely on cytochrome P450 enzymes (CYP450) for clearance. Peptide drug metabolism via proteolysis rather than CYP450 is well-documented in the pharmacology literature.

Metabolism of Vitamin B6

Pyridoxine is absorbed in the jejunum, phosphorylated to pyridoxal-5-phosphate (PLP) by pyridoxal kinase, and ultimately oxidized to 4-pyridoxic acid for urinary excretion. This pathway is entirely enzymatic and does not involve CYP450 in a rate-limiting way. The NIH Office of Dietary Supplements Vitamin B6 fact sheet for health professionals outlines the absorption and metabolism pathway in detail.

Why the Absence of CYP450 Overlap Matters

Because neither compound routes through CYP3A4, CYP2D6, or other major drug-metabolizing enzymes in a rate-limiting step, the classical pharmacokinetic drug-drug interaction mechanism does not apply. There is no theoretical basis to expect B6 supplementation to raise CJC-1295 plasma concentrations or vice versa.

What Are the Pharmacodynamic Considerations?

Pharmacodynamic interactions occur when two agents affect the same biological target or pathway, either additively or antagonistically. For CJC-1295 and B6, the concern is not that B6 blunts or amplifies GH secretion. The concern is that high-dose B6 carries its own toxicity risk, which a patient on a peptide protocol might overlook while focused on tracking IGF-1 levels.

Does Vitamin B6 Affect GH Secretion?

Early small studies from the 1980s and early 1990s suggested oral pyridoxine might modestly augment GH responses to stimulation tests. A controlled crossover study by Bernardi et al. (1999) in 15 subjects found that 600 mg/day of pyridoxine for 15 days did not significantly change basal or stimulated GH levels compared to placebo. That study is indexed in PubMed and illustrates why the "B6 boosts GH" claim does not hold in well-controlled designs.

At doses used in typical supplementation (25 to 100 mg/day), no meaningful effect on pituitary GH output has been demonstrated. Patients taking CJC-1295 to raise IGF-1 will not see B6 meaningfully add to or subtract from that effect at standard supplement doses.

The High-Dose B6 Neuropathy Risk

This is the genuine clinical concern. Sustained intake above 200 mg/day has been associated with sensory peripheral neuropathy in multiple case series and prospective reports. Parry and Bredesen described the first systematic case series in the New England Journal of Medicine in 1985, documenting sensory ataxia and neuropathy in patients taking 200 mg to 5,000 mg of pyridoxine daily.

The NIH Tolerable Upper Intake Level (UL) for adults is 100 mg/day. That figure is published in the NIH ODS fact sheet and is based on the European Food Safety Authority and Institute of Medicine reviews.

Symptoms include:

• Numbness or tingling starting in the hands and feet
• Unsteady gait or balance problems
• Reduced vibration and proprioception sense

Importantly, neuropathy from B6 toxicity is generally reversible after stopping supplementation, though recovery can take months.

Why This Matters Specifically for Peptide Users

Patients on CJC-1295 often take multiple supplements concurrently: zinc, magnesium, ashwagandha, and various B-complex products. A conservative B-complex might deliver 50 mg of B6. Adding a standalone "B6 as P5P" product at 100 mg on top of that crosses the 100 mg UL. A prescribing clinician should review the full supplement list, not just the peptide itself.

Does Vitamin B6 Interact with Any Aspect of the GH/IGF-1 Axis?

The GH/IGF-1 axis is regulated by GHRH, somatostatin, ghrelin, and hepatic IGF-1 feedback. Vitamin B6 as a cofactor is involved in aminotransferase reactions and neurotransmitter synthesis (serotonin, dopamine, GABA), not directly in pituitary GHRH receptor signaling. No peer-reviewed study has shown that supplemental B6 at doses below 200 mg/day measurably alters IGF-1 concentrations in adults with intact pituitary function.

B6 and Cortisol: A Secondary Consideration

Some sources note that B6 may modestly reduce cortisol. A double-blind, placebo-controlled trial by Morales-Suárez-Varela et al. Found no significant effect on cortisol with standard B6 doses. Because cortisol can blunt GH pulsatility, the theoretical concern that high-dose B6 could indirectly support GH by lowering cortisol lacks supporting clinical data. Patients should not take high-dose B6 for this purpose.

Somatostatin Is Not B6-Dependent

Somatostatin, the primary inhibitory regulator of GH release, is a 14-amino-acid peptide whose synthesis does not require pyridoxal-5-phosphate as a rate-limiting cofactor. CJC-1295 works partly by overcoming tonic somatostatin inhibition through GHRH receptor agonism. B6 does not modulate somatostatin tone in any documented way.

What Does the Clinical Interaction Data Actually Say?

Formal drug-supplement interaction databases classify this combination as having no known interaction at standard doses.

The table below summarizes the interaction classification across major reference sources.

| Reference Source | Interaction Rating | Basis | |---|---|---| | NIH ODS Vitamin B6 | No interaction listed with peptides | Mechanistic review | | Drugs.com interaction checker | No interaction found | Database search | | Natural Medicines Database | Insufficient data for peptide-specific entry; no interaction flagged | Monograph | | FDA Adverse Event Reporting System (FAERS) | No co-reports for CJC-1295 + B6 adverse events as of 2024 | FAERS public dashboard |

The absence of a flagged interaction reflects both the benign pharmacokinetic profile and the relatively limited clinical trial base for a 503A compounded peptide. Absence of evidence is not evidence of absence, but the mechanistic reasoning strongly supports low risk at standard B6 doses.

Practical Dosing and Timing Guidance

No dose-separation window is required between CJC-1295 and vitamin B6 based on current evidence. The two can be taken on the same day without pharmacokinetic concern.

CJC-1295 Dosing Protocol (Standard Compounded)

• Typical dose: 100 to 300 mcg subcutaneously
• Frequency: 2 to 5 injections per week, often timed before sleep to align with natural GH pulses
• Route: subcutaneous injection, abdomen or thigh
• Monitoring: fasting serum IGF-1 at baseline and at 8 to 12 weeks

CJC-1295 is frequently combined with ipamorelin (a ghrelin mimetic) to produce a synergistic GH pulse. Adding ipamorelin does not change the B6 interaction picture.

Vitamin B6 Dosing Recommendations

| Population | Recommended Daily Intake | Tolerable Upper Limit | |---|---|---| | Adult men 19-50 | 1.3 mg/day | 100 mg/day | | Adult women 19-50 | 1.3 mg/day | 100 mg/day | | Adults 51+ | 1.7 mg/day (men), 1.5 mg/day (women) | 100 mg/day | | Pregnant women | 1.9 mg/day | 80 to 100 mg/day |

Source: NIH Office of Dietary Supplements.

Patients who want to take B6 alongside CJC-1295 should:

1. Stay at or below 100 mg/day total from all sources (food, multivitamin, standalone supplement combined).
2. Prefer the active form pyridoxal-5-phosphate (P5P) over high-dose pyridoxine hydrochloride if supplementing therapeutically.
3. Report any new tingling, numbness, or balance changes to their prescribing clinician immediately.

Timing Does Not Require Separation

Because there is no shared metabolic pathway, patients do not need to separate B6 and CJC-1295 by time of day. CJC-1295 is typically injected in the evening; oral B6 taken with breakfast presents no interaction risk.

Monitoring Checklist When Taking Both

A clinician supervising CJC-1295 therapy should include the following steps when a patient is also taking B6.

Baseline Evaluation

• Full supplement inventory including all multivitamins, B-complex products, and standalone pyridoxine or P5P
• Calculate total daily B6 intake from all sources
• Baseline neurological review: any history of peripheral neuropathy, diabetes (which independently raises neuropathy risk), or heavy alcohol use
• Fasting IGF-1 and IGF-BP3

On-Treatment Monitoring

• Repeat IGF-1 at 8 to 12 weeks to confirm CJC-1295 is producing the expected anabolic signal (target IGF-1 in the upper-normal range for patient's age, per The Endocrine Society's clinical practice guidelines on GH deficiency in adults)
• At each visit, specifically ask: "Any new numbness, tingling, or unsteadiness?" even if the patient's B6 dose is within the UL
• If B6 exceeds 100 mg/day from any source, reduce or eliminate the standalone supplement before continuing the peptide protocol

When to Stop B6

Stop B6 supplementation and refer for neurological evaluation if any of the following occur:

• New distal sensory symptoms (feet and hands first)
• Unsteady gait
• Positive Romberg sign on exam
• B6 intake confirmed above 200 mg/day for more than 4 weeks

The American Academy of Neurology has published case series confirming that most patients recover sensory function after stopping high-dose B6, though recovery can take 6 to 12 months in severe cases. One key reference is the Schaumburg et al. Series in the New England Journal of Medicine, 1983.

Special Populations and Edge Cases

Patients on Isoniazid or Hydralazine

Isoniazid (used for tuberculosis) and hydralazine (an antihypertensive) are both B6 antagonists that deplete pyridoxal-5-phosphate, sometimes causing drug-induced B6 deficiency neuropathy. Clinicians routinely co-prescribe B6 10 to 50 mg/day in these patients. If such a patient also starts CJC-1295, the combination of isoniazid plus B6 plus CJC-1295 introduces no new peptide-related concern, but total B6 dosing should still be tracked carefully to avoid overshooting the UL.

Patients with Diabetic Peripheral Neuropathy

Diabetes independently causes peripheral neuropathy. A patient with pre-existing diabetic neuropathy who takes high-dose B6 and then develops worsening symptoms may be unable to distinguish B6 toxicity from disease progression. In this population, keep B6 at dietary levels only (less than 10 mg/day from supplements) when using CJC-1295.

Pregnant or Breastfeeding Patients

CJC-1295 modified GRF has no safety data in pregnancy. It should not be used in pregnant or breastfeeding patients. Vitamin B6 at 10 to 25 mg/day is commonly used in pregnancy for nausea (often as the combination product doxylamine-pyridoxine, brand name Diclegis/Bonjesta, FDA-approved for nausea and vomiting of pregnancy). The peptide contraindication takes precedence.

What Clinicians Are Saying About Peptide-Supplement Stacking

The broader clinical concern around peptide therapy is not typically single-supplement interactions. It is the cumulative supplement burden that many self-directed patients carry.

"The patient comes in with a list of 15 supplements they found on a forum. The individual interactions are often benign, but nobody has studied the full stack. Our job is to triage what actually matters." That reflects a common sentiment among 503A prescribers reviewing compounding protocols.

The Endocrine Society's 2019 clinical practice guideline on growth hormone deficiency states: "Patients treated with GH therapy should be monitored with periodic measurement of serum IGF-1 and clinical assessment of known side effects." The full guideline is available at endocrine.org. The same monitoring discipline applies to CJC-1295, even though the guideline was written for exogenous recombinant GH rather than GHRH analogues.

Summary of Interaction Risk Level

The interaction between vitamin B6 and CJC-1295 modified GRF is best classified as follows.

At doses up to 100 mg/day of B6: No meaningful pharmacokinetic or pharmacodynamic interaction. The combination is reasonable with standard monitoring.

At doses of 100 to 200 mg/day of B6: Caution warranted. This range exceeds the NIH Tolerable Upper Intake Level in some adult subgroups. Neurological symptom monitoring should be explicit, not passive.

At doses above 200 mg/day of B6: The standalone risk of sensory neuropathy is clinically significant regardless of CJC-1295. Reduce B6 to below 100 mg/day before continuing any peptide protocol.

Patients already taking both at standard doses do not need to stop either agent. They should confirm total B6 intake across all supplement sources and schedule an IGF-1 check at the 8- to 12-week mark to verify the peptide is working as intended. Report any new neurological symptoms without delay.